The results of pilot trial ALL-REZ-MВ-2014 for children with relapsed acute lymphoblastic leukemia

The relapse of acute lymphoblastic leukemia (ALL) in children is still a difficult task. This is due both to the difficulties of achieving a second remission and to the problems of organizing allogeneic bone marrow  transplantation (BMT) in those patients who need it. The standard approach is the use of second-line drugs  in the regime of high-dosage chemotherapy blocks, but the response rate for this treatment in patients with  early relapses remains low and the response time is short. Recently, new drugs with different  mechanisms of action have appeared that can give an opportunity for a full remission. The organization of a multicentre study on anti-relapse therapy in the Russian Federation is an urgent task, the solution of which  can help in studying new approaches to therapy and in the organization of BMT logistics. This article  presents the results of a pilot multicentre study on the treatment of relapses of ALL in children in the  Russian Federation. The effectiveness of standard therapy for a group with late relapses and the efficacy and toxicity of interventional blocks with the use of bortezomib, clofarabine, nelarabine are presented.